Versant Venture Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Versant Venture Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 12, 2019	SELL	$6.05 - $13.66 $3.27 Million - $7.39 Million	-540,943 Reduced 49.87%	543,753 $3.89 Billion
Q3 2018 Oct 05, 2018	BUY	$10.88 - $14.52 $392,713 - $524,099	36,095 Added 3.44%	1,084,696 $12 Billion
Q3 2017 Oct 13, 2017	BUY	$5.95 - $8.26 $6.24 Million - $8.66 Million	1,048,601	1,048,601 $8.26 Billion

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Versant Venture Management, LLC with notifications on news.